BCC Research’s recent report breaks down the opportunities and risks for nanoparticles in biotechnology, drug developments, and drug delivery systems. Providing five-year forecasting and regional analysis, the report acts as an excellent accomplice for those navigating the landscape.
Nanotechnology research is an expensive area; strong infrastructure and financial muscle are required. The research is being done largely by developed nations, which is causing concern about whether less financially strong countries can afford to develop the nanotechnology industry. Moreover, the nanoparticles' physical synthesis methods are highly expensive, while chemical synthesis methods have slow growth rates, inaccuracy of structure, and pose serious environmental risks. The bottom-up approach of synthesizing nanoparticles which begins with initial structures at the atomic level is a cost-effective method for large-scale productions in contrast with a top-down approach which begins with initial structures at the macroscopic level. For firms that make nanotherapeutics, cost is a huge hurdle. Manufacturing nanodrugs is substantially more expensive than producing traditional drugs. The everyday success of nanomedicines is hampered by these economies of scale, which result in significantly higher selling prices or acquisition costs for hospitals.
The nanoparticles industry is witnessing increasing investments, which is prompting the market for continued expansion. To develop an effective strategy, knowing the opportunity areas is essential.
You could consider becoming a member of the BCC Research library. Membership offers unlimited access to the full scope of reports within your chosen category. Explore the biotechnology category today and enquire today to find out more.
We are your trusted research partner, providing actionable insights and custom consulting across life sciences, advanced materials, and technology. Allow BCC Research to nurture your smartest business decisions today, tomorrow, and beyond.Contact Us